X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $304.30M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 0.64M
Average 0.40M
XFOR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
X4 Pharmaceuticals, Inc.NASDAQ: XFOR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$20.24M, compared with $282K a year earlier. Trailing-twelve-month net income was -$99.72M. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Net income amounted to 225.6% of revenue in FY2025, down 1239.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$26.28M (-66.8%) for the fiscal year ending Dec 2026, a slowdown from the +111.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.24M-15.4% QoQ
- Last fiscal yearDec 2025
- -$79.2M+111.5% YoY
- LTMMar 2026
- -$99.72M-783.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7277.7% | -13.5% | +7264.2 pp |
| 1 year | +111.5% | -66.8% | -178.3 pp |
| 3-year CAGR | -5.5% | -22.5% | -17.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (79.2M) USD
- Year-over-year change
- -111.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.2M) | -111.5% |
| FY2024 | 2024-12-31 | (37.45M) | +63.0% |
| FY2023 | 2023-12-31 | (101.17M) | -7.8% |
| FY2022 | 2022-12-31 | (93.87M) | -5.8% |
| FY2021 | 2021-12-31 | (88.7M) | — |
Net Income vs competitors
How XFOR compares with its peers on the latest reported figures
- XFOR's LTM Mar 2026 net income of $99.72M is the 2nd largest of the 4 companies compared; the peer median is $58.75M.
- Its year-over-year change of -783.1% is the lowest of 4, against a peer median of +110.8%.
- Net income amounts to 1106.3% of revenue for XFOR, versus a peer median of 129.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
| LTM Mar 2026 | $99.72M | -783.1% | -5.5% | 1106.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $58.75M | -23.5% | +26.3% | — |
| LTM Mar 2026 | $4.41M | +110.8% | +18.9% | — | |
| Peer median (excluding XFOR) | $58.75M | +110.8% | +18.9% | 129.0% | |
Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (88.7M) | (93.87M) | (101.17M) | (37.45M) | (79.2M) |
| Depreciation & Amortization | 1.89M | 513K | 419K | 796K | 1.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 5.2M | 8.69M | 8.2M | 4.3M |
| Change in Working Capital | (1.5M) | 5.74M | 344K | 2.68M | (2.58M) |
| Accounts Receivables | 0 | 0 | 0 | (1.07M) | 497K |
| Inventory | 0 | 0 | 0 | (2.82M) | (1.66M) |
| Accounts Payables | 1.17M | 3.43M | 1.23M | (286K) | (2.98M) |
| Other Working Capital | (2.66M) | 2.31M | (890K) | 6.85M | 1.57M |
| Other Non-Cash Items | 17.4M | 5.32M | (4.8M) | (105.13M) | (9.42M) |
| Operating Cash Flow | (70.91M) | (77.1M) | (96.51M) | (130.9M) | (85.62M) |
| Capital Expenditures | (615K) | (103K) | (60K) | (7.33M) | (3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (16.82M) | (57.13M) | (63.39M) |
| Sales of Investments | 0 | 0 | 2M | 26.45M | 74.54M |
| Other Investing Activities | 0 | 0 | 0 | 98M | 0 |
| Investing Cash Flow | (615K) | (103K) | (14.88M) | 66.99M | 8.15M |
| Debt Repayment | 0 | (795K) | 20.44M | 20M | 0 |
| Common Stock Issued | 76.25M | 122.63M | 60M | 294K | 238.53M |
| Common Stock Repurchased | (2M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.61M) | 8.08M | 0 | 98K |
| Financing Cash Flow | 74.25M | 117.23M | 88.52M | 20.29M | 238.63M |
| Effect of Forex Changes | 90K | (105K) | 99K | (156K) | 213K |
| Net Change in Cash | 2.82M | 39.92M | (22.78M) | (43.77M) | 161.38M |
| Free Cash Flow | (71.52M) | (77.21M) | (96.57M) | (138.23M) | (88.62M) |
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.